These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 11834180)

  • 41. Stepping down from high dose fluticasone/salmeterol to extrafine BDP/F in asthma is cost-effective.
    Paggiaro P; Patel S; Nicolini G; Pradelli L; Zaniolo O; Papi A
    Respir Med; 2013 Oct; 107(10):1531-7. PubMed ID: 23916740
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of the cost-effectiveness of budesonide and sodium cromoglycate in the management of childhood asthma in everyday clinical practice.
    Andersson F; Kjellman M; Forsberg G; Möller C; Arheden L
    Ann Allergy Asthma Immunol; 2001 May; 86(5):537-44. PubMed ID: 11379805
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Financial payment systems and asthma care.
    Sumner B; Lurie N
    Med Care; 1993 Mar; 31(3 Suppl):MS74-81. PubMed ID: 8450688
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Asthma treatment guidelines: how do we measure up?
    Navarro RP
    Am J Manag Care; 2005 Nov; 11(14 Suppl):S422-6; quiz S427-33. PubMed ID: 16300463
    [TBL] [Abstract][Full Text] [Related]  

  • 45. An economic evaluation of budesonide/formoterol for maintenance and reliever treatment in asthma in general practice.
    Goossens LM; Riemersma RA; Postma DS; van der Molen T; Rutten-van Mölken MP
    Adv Ther; 2009 Sep; 26(9):872-85. PubMed ID: 19768640
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Are there specific treatments for allergic asthma?].
    Didier A; De Blay F; Tetu L; Dubus JC; Grimfeld A; Just J; Demoly P
    Rev Mal Respir; 2007 Oct; 24(8 Pt 3):7S41-51. PubMed ID: 18033202
    [No Abstract]   [Full Text] [Related]  

  • 47. Costs associated with asthma treatment.
    Barbers R
    Curr Opin Pulm Med; 1998 Jan; 4(1):1-3. PubMed ID: 9526897
    [No Abstract]   [Full Text] [Related]  

  • 48. Economic realities and the health plight of Americans.
    Wolf BL
    Ann Allergy Asthma Immunol; 2015 Sep; 115(3):170-1. PubMed ID: 26231466
    [No Abstract]   [Full Text] [Related]  

  • 49. Pressure point. When coughing up is essential.
    Cooper C
    Health Serv J; 2000 Nov; 110(5733):suppl 1. PubMed ID: 11138527
    [No Abstract]   [Full Text] [Related]  

  • 50. Response to Campbell, Spackman, Sullivan letter to Allergy.
    Brown R; Turk F; Dale P; Bousquet J
    Allergy; 2008 Jun; 63(6):783. PubMed ID: 18445194
    [No Abstract]   [Full Text] [Related]  

  • 51. [Omalizumab and allergen immunotherapy: A clinical report and review of the literature].
    Carrier C; Demoly P; Caimmi D
    Rev Mal Respir; 2019 Feb; 36(2):191-196. PubMed ID: 30396780
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Use of omalizumab to improve desensitization safety in allergen immunotherapy.
    Larenas-Linnemann D; Wahn U; Kopp M
    J Allergy Clin Immunol; 2014 Mar; 133(3):937-937.e2. PubMed ID: 24581432
    [No Abstract]   [Full Text] [Related]  

  • 53. [Quality assurance of drug therapy for patients with asthma. Health economic analysis].
    Søndergaard B; Thorleifsson S; Herborg H; Frøkjaer B; Hepler CD; Ersbøll BK
    Ugeskr Laeger; 2000 Jan; 162(4):480-6. PubMed ID: 10697444
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [It has come this far. The industry determines what is healthy].
    Pandalis G
    MMW Fortschr Med; 2004 Apr; 146(18):18. PubMed ID: 15366464
    [No Abstract]   [Full Text] [Related]  

  • 55. [Cost-of-illness of asthma in Denmark in the year 2000].
    Mossing R; Nielsen GD
    Ugeskr Laeger; 2003 Jun; 165(26):2646-9. PubMed ID: 12886546
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Economic and health effect of full adherence to controller therapy in adults with uncontrolled asthma: a simulation study.
    Zafari Z; Lynd LD; FitzGerald JM; Sadatsafavi M
    J Allergy Clin Immunol; 2014 Oct; 134(4):908-915.e3. PubMed ID: 24875619
    [TBL] [Abstract][Full Text] [Related]  

  • 57. An evaluation of the cost-effectiveness of omalizumab for the treatment of severe allergic asthma.
    Sullivan SD; Turk F
    Allergy; 2008 Jun; 63(6):670-84. PubMed ID: 18445184
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Economic analysis of biological therapies for severe asthma treatment.
    Almonacid-Sánchez C; Melero-Moreno C
    Farm Hosp; 2019 Nov; 43(6):175-176. PubMed ID: 31705639
    [No Abstract]   [Full Text] [Related]  

  • 59. Adding formoterol to budesonide in moderate asthma--health economic results from the FACET study.
    Andersson F; Stahl E; Barnes PJ; Löfdahl CG; O'Byrne PM; Pauwels RA; Postma DS; Tattersfield AE; Ullman A;
    Respir Med; 2001 Jun; 95(6):505-12. PubMed ID: 11421509
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Trends and predictors of asthma costs: results from a 10-year longitudinal study.
    Tan NC; Nguyen HV; Lye WK; Sankari U; Nadkarni NV
    Eur Respir J; 2016 Mar; 47(3):801-9. PubMed ID: 26647437
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.